BioVaxys Technology Corp. Announces Appointment of New Director

Vancouver, British Columbia--(Newsfile Corp. - October 21, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (formerly Lions Bay Mining Corp.) ("BioVaxys" or the "Company") is pleased to announce that David Wang and Darren Hermiston have been appointed as directors of the Company. Mr. Hermiston replaces Timothy Heenan, who has resigned to pursue other endeavors. The Company would like to sincerely thank Mr. Heenan for his contributions. The Board of Directors is now comprised of James Passin (Chief Executive Officer), Jeremy Poirier, David Wang, and Darren Hermiston.

David Wang, a seasoned medical technology executive, is Healthcare Consultant for South America for Omron, an USD$1.5 billion market capitalization company listed on the Tokyo Stock Exchange. Mr. Wang is the former CEO of CAUS Capital and the former CEO of Beijing Century Medical and is fluent in Chinese and Japanese.

Mr. Hermiston is the founder and CEO of Kona Consulting Inc. and acts as an Agent with PointsWest Sports and Entertainment representing hockey players for over 11 years. Mr. Hermiston has an extensive background in marketing public and private companies throughout various sectors and is a guest lecturer at Simon Fraser University (SFU) for Sports and Entertainment Marketing. Mr. Hermiston also currently holds positions with a number of private companies, including acting as a director of Baden Resources Inc., which has filed a preliminary prospectus and is seeking a listing on the CSE.

In addition, the Company announces that it has granted an aggregate of 3,000,000 incentive stock options (the "Options") to certain officers and directors. The Options are each exercisable for one common share at an exercise price of $0.45 for five years and vest over a two-year period.

Signed "James Passin"
Chief Executive Officer

FOR FURTHER INFORMATION PLEASE CONTACT:
James Passin, Chief Executive Officer - Telephone: 1-646-452-7054

ABOUT BIOVAXYS TECHNOLOGY CORP.

The Company is an early stage clinical biotechnology company developing antiviral and anticancer vaccines and therapeutic platforms.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66429